Strategies For Orphan, Breakthrough And Fast Track Designated Oral Solid Development Programs

Presenter: Richard J. Holl and Todd Stutzman

Summary: There are critical unmet needs to get new drugs to market in order treat life threatening diseases. Accelerated regulatory pathways of fast track and breakthrough designations can often shave years off the approval process. Richard J. Holl, PhD and Todd Stutzman, Pharm.D., Directors at Catalent discuss how different development approaches and solutions can save time and accelerate your project from development to commercialization.

Watch it Now

お問い合わせ

    東京オフィス
    〒107‐0052
    東京都港区赤坂4−9−17
    T (03) 3470-2311
    F (03) 3408-5554

    掛川工場
    〒436‐0341
    静岡県掛川市倉真1656
    T(0537) 29-1131